New cocktail of three drugs aims to tackle rare lymphoma
NCT ID NCT07299331
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This study tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as the first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. The trial will enroll 50 adults aged 18-75 with advanced disease who haven't had treatment yet. Researchers want to see if this combo can shrink tumors and keep the cancer from coming back, while also tracking any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib, rituximab, and lenalidomide
What this could lead to
If successful, this combination could offer a new first-line treatment option for marginal zone lymphoma, potentially improving remission rates and delaying disease progression.
What could go wrong
This is a small, early-phase study (50 people) with no control group, so results may not be definitive. The three-drug combo also carries risks like infection, low blood counts, and other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.